Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02347098 · ClinicalTrials.gov registry record · Phase 3
Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II
A Phase 3 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 270
- Enrollment target
NCT02347098: Completed Phase 3 study, sponsored by VA Office of Research and Development.
NCT02347098 is a Phase 3 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 270 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02347098, a Phase 3 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 270 participants
- Enrollment target
Study Summary
The purpose of this randomized, multi-site, clinical trial is to determine whether intensive therapy consisting of cholesterol-lowering statin drugs plus apheresis to cleanse the blood of low-density lipoprotein (LDL) cholesterol is more effective than statin therapy alone in reducing plaque volume in heart arteries of patients who have already suffered an acute coronary syndrome (ACS). The study will also investigate whether this intensive approach can help increase the presence of endothelial progenitor cells (EPC), stem cells that have been shown to reduce cardiovascular (CV) events in ACS patients. This study has two phases and FDA approval for phase II has been received and all information has been updated to reflect PREMIER Phase II.
Interventions
- DEVICE intensive LDL-lowering therapy
- DRUG standard statin monotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2015-03-30 |
| Est. Completion | 2019-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02347098
The ClinicalTrials.gov registry entry for NCT02347098 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which intensive LDL-lowering therapy is the first listed.
NCT02347098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02347098 about?
NCT02347098 is a clinical study titled "Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II". The purpose of this randomized, multi-site, clinical trial is to determine whether intensive therapy consisting of cholesterol-lowering statin drugs plus apheresis to cleanse the blood of low-density lipoprotein (LDL) cholesterol is more effective than statin therapy alone in reducing plaque volume ...
What is the current status of trial NCT02347098?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 270 participants. The study started on 2015-03-30. Estimated completion is 2019-09-30.
What interventions are being tested in trial NCT02347098?
The interventions under investigation include: intensive LDL-lowering therapy (DEVICE), standard statin monotherapy (DRUG).
Who is sponsoring clinical trial NCT02347098?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.